NSABP TREATMENT B21

NSABP 治疗 B21

• 批准号: 7607568
• 负责人: Scott Henry Kurtzman
• 金额: $ 0.02万
• 依托单位: UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607568
• 关键词: Axillary lymph node group; Benign; Breast; Caliber; Carcinoma; Clinical; Computer Retrieval of Information on Scientific Projects Database; Dissection; Funding; Grant; Institution; Invasive; Lesion; Measures; National Surgical Adjuvant Breast and Bowel Project; Pathologic; Patients; Placebos; Radiation; Randomized; Reporting; Research; Research Personnel; Resected; Resources; Source; Specimen; Tamoxifen; United States National Institutes of Health; breast lumpectomy; size; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Patients eligible for this study must have had a lumpectomy with tumor-free specimen margins and axillary node dissection with pathologically-negative axillary nodes. The largest tumor diameter, by pathological examination of the resected specimen, must be < 1 cm. If the pathologic tumor size is indeterminable from the report, then the maximum clinical and mammographic tumor sizes must both be < 1 cm. If a tumor pathologically consists of both an invasive component and an intraductal component, then the maximum diameter of both components when measured together must be < 1 cm. Finally, patients are eligible if a carcinoma pathologically < 1 cm in size is detected in association with a benign lesion of any size. Patients in this study will be randomly assigned to one of three groups: lumpectomy and breast radiation plus placebo, lumpectomy and breast radiation plus tamoxifen, or lumpectomy, tamoxifen and no breast radiation.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 符合这项研究条件的患者必须接受无肿瘤标本边缘的肿块切除术和腋窝淋巴结清扫术，但腋窝淋巴结病理阴性。根据切除标本的病理检查，肿瘤的最大直径必须为1厘米。如果病理肿瘤的大小不能从报告中确定，那么临床和乳房X光检查的肿瘤的最大大小必须都是1厘米。如果一个肿瘤在病理上由侵袭性成分和导管内成分组成，那么当两种成分一起测量时，最大直径必须为1厘米。最后，如果在病理上检测到1厘米大小的癌与任何大小的良性病变相关，患者就符合条件。这项研究中的患者将被随机分配到三组中的一组：肿块切除加乳房放射加安慰剂，肿块切除加乳房放射加他莫昔芬，或肿块切除加他莫昔芬，不做乳房放射。